We have investigated the interaction of clotrimazole (CLT) and related compounds with the erythroid Ca2"-activated K+ channel, a mediator of sickle cell dehydration. We measured K+ transport, membrane potential, and cell volume upon activation of this pathway in sickle erythrocytes. CLT blocked almost completely Ca2"-activated K+ transport in homozygous hemoglobin S cells, with IC5o values of 29±15 nM in isotonic 20 mM salt solution and 51±15 nM in normal saline (n = 3). The inhibition of K+ transport by CLT was caused by a specific interaction with the Ca2"-activated K+ channel of human red cells, since it displaced bound 125I-Charybdotoxin, a specific ligand of the Gardos channel, with an IC50 (12±4 nM in isotonic 20 mM) similar to the IC50 values for flux inhibition. When homozygous hemoglobin S cells were dehydrated by incubation in the presence of 100 ,gM CaCI2 and the ionophore A23187, or by exposure to cycles of oxygenation and deoxygenation, CLT effectively inhibited cell dehydration and K+ loss. The IC50 of CLT for inhibition of Ca2+-activated K+ transport in sickle cells is significantly lower than plasma concentrations of CLT achievable after nontoxic oral doses. We therefore propose that oral administration of CLT may prevent red cell dehydration in patients with sickle cell anemia. (J. Clin. Invest. 1993. 92:520-526.)
Introduction
The reduced red cell water content observed in sickle cell anemia has important implications for the pathogenesis ofthe disabling clinical complications of hemoglobin S (Hb S) polymerization and sickling (1) . The erythrocyte fractions of highest 1 . Abbreviations used in this paper: AA, normal subjects or red cells containing hemoglobin A; CCCP, carbonyl cyanide m-chlorophenyl hydrazone; ChTX, charybdotoxin; CLT, clotrimazole; DIDS, diisothiocyano-disulfonyl stilbene; HC, hemoglobin concentration; density in homozygous hemoglobin S (SS)' disease are characterized by severe dehydration with mean corpuscular hemoglobin concentrations (MCHC) as high as 40-50 g/dl (2, 3) . The high order exponential dependence of the delay time for Hb S polymerization on the concentration of Hb S suggests that extremely small increases in intracellular Hb S concentration will disproportionately reduce the delay time. The resultant acceleration of Hb S polymerization is thought to increase cell sickling before exit of erythrocytes from the confines of the capillary (1) .
Prevention of MCHC elevation is one of a limited number of strategies available to decrease Hb S polymerization and cell sickling in SS patients. Several methods of prevention have undergone clinical study, including attempts to increase Hb F production relative to Hb S, and attempts to prevent cell dehydration (1) . Prevention of cell dehydration can in theory be approached by osmotic promotion ofswelling or by pharmacologic prevention ofthe cell shrinkage normally provoked by the acidic, hypoxic environment of the capillary bed. The first attempt to reduce MCHC osmotically by therapeutic induction of hyponatremia did, indeed, produce reductions in both cell sickling and clinical symptoms (4) . However, prolonged maintenance of the requisite (occasionally symptomatic) degree of hyponatremia required compliance with a very challenging dietary regimen.
Cell shrinkage is mediated by loss of intracellular KCl with accompanying water. Studies ofthe membrane transport properties of SS erythrocytes have indicated that two transport pathways play a dominant role in K+ loss from and dehydration of sickle cells. One pathway is the volume and pH-regulated K-Cl cotransport system (3, 5) . Though K-Cl cotransport activity is lower in the densest SS cells than in corresponding light and middle-density fractions, activity in these densest fractions is still higher than in AA inhibited by quinine, carbocyanine dyes (9), nifedipine (10), and nitrendipine ( 11) and with greater specificity by charybdotoxin (ChTX), a 37-amino acid peptide derived from the venom of Leiurus sequestratus (12) (13) (14) . None of these drugs has been brought to clinical trial in sickle cell anemia, resulting either from low inhibitory potency (of the former) or from insufficient pharmacological specificity (of the latter) with expected attendant side effects. Recent work on cytochrome P450-related electron transport has led to a report that imidazole antimycotic drugs are potent inhibitors of the Ca2+-activated K+ channel in normal human red cells (15) . We have investigated the effects ofimidazole and triazole antimycotics and of nitroimidazoles in SS erythrocytes, with the intention of evaluating their ability to inhibit K+ transport and cell dehydration mediated by the Gardos channel. Our long-term objective is to identify compounds that could be clinically useful in SS patients to prevent cell dehydration and to diminish irreversible sickling and microvascular obstruction. Our results suggest that clotrimazole (CLT) or related drugs could be used to prevent dehydration of SS cells in vivo.
Methods

Patient selection
Patients homozygous for Hb S disease were selected for this study. (16) . The "physiological ionic strength" medium contained 140 mM NaCl, 2 mM KC1, and 10 mM Tris-HCl, pH 8 .0. At the end of the incubation triplicate samples of cell suspension were spun at 3,000 g for 10 min, the supernatant was removed and a smaller volume of medium containing A23 187 (60 Jmol/liter cells), 50 uM CaCl2, and 86Rb (1 ACi/ml) was added to a final hematocrit (Hct) of 4-5%. This cell suspension was agitated at room temperature, aliquots were sampled at 1-, 3-, and 5-min time points, then spun in a microfuge through 0.8 ml of chilled flux medium containing 5 mM EGTA layered over a 0.4 ml cushion of butyl-phthalate oil. The resultant supernatant and the upper layer of oil were carefully aspirated, the remaining tube contents were frozen in a dry ice/acetone mixture, and the tube tips containing the cell pellet were cut off and counted. The initial rate of 86Rb transport, a measure of K+ transport through the Ca2-activated pathway, was calculated from the linear least square derived slope. Inhibitory constants were calculated by computer-assisted nonlinear curve fitting (Ultrafit 2.0; Biosoft).
Measurement of'25I-ChTX binding to red cells White cells were removed by passing 0.8 ml of packed red cells through a 5-ml syringe containing a mixture of equal parts of alfa-cellulose and microcrystalline cellulose as originally described by Beutler and West (17) . Red cells were washed three times in binding medium containing 18 mM NaCl, 2 mM KCl, 10 mM Tris-Cl, pH 8.0, 230 mM sucrose, and 0.25% bovine serum albumin. A suspension was made in the same medium at 15% Hct. Cells were added to 3.5 ml of binding medium containing '251I-ChTX to a final concentration of 1 x 107 cells/ml, in the absence or presence of the specified drugs. Tubes containing cell suspension were gently rotated for 90 min at room temperature. At the end of the incubation, aliquots of 1 ml were pelleted by microfuge and washed three times at 4VC with a solution containing 200mM NaCl, 10 mM Tris-Cl, pH 8.0. The washed red cell pellet was lysed in 1 ml of 0.01% Acationox', and counted in a gamma counter. Aliquots of cellfree binding medium were counted before addition of cells and at the end of the assay.
Measurement of membrane potential in red cells
Measurements of the proton distribution ratio in unbuffered media in the presence of the proton ionophore CCCP were used to estimate red cell membrane potential (18) .
Measurement of Ca2"-dependent erythrocyte dehydration
Experiments with A23187. Cells were incubated for 60 min at 370C in a medium containing 140 mM NaCl, 4 mM KC1, 100 ,M CaCl2, 1 mM K-phosphate buffer, 10 mM Tris-Mops, pH 7.40, at 1-2% Hct with the specified inhibitors. A23 187 was subsequently added to a final concentration of 60 ztmol/liter cells under stirring. At the specified times, the cell suspension was diluted with an equal amount of medium containing 5 mM EGTA and 0.1% BSA, to chelate extracellular Ca2' and remove A23 187. The red cells were then washed four times with the same medium at 37°C. An aliquot of the washed cells was used to measure the distributions of cell volume and hemoglobin concentration with a blood analyzer (H*2 Technicon; Miles Diagnostic Inc., Tarrytown, NY; reference 19). The remaining cells were washed four more times with choline washing solution (144 mM choline Cl, 1 mM MgCl2, 10 mM Tris-Mops, pH 7.40 at 4°C) for measurements of internal Na and K contents by atomic absorption spectrometry (3).
Exposure to oxygenation-deoxygenation cycles. Cells were incubated at 37°C and 10% Hct in a medium containing 110 mM NaCl, 25 mM Na bicarbonate, 5 mM KC1, 1 mM Na-phosphate buffer, pH 7.40, 1 mM MgCl2, 5 mM glucose, and 0.01% bovine serum albumin. Media also contained either 2 mM Ca C12 (±10 IM CLT) or 1 mM EGTA. Cells were exposed to repeated cycles of 1 min at 15% 02, 5% CO2, and 4 min at 5% CO2 (gases were balanced with N2 and hydrated in gas washers containing assay medium). After 1 or 3 h, cells were harvested for cation content, cell volume, and hemoglobin concentration measurements.
Measurements of35S-sulfate influx into AA erythrocytes 35S-sulfate uptake into AA red cells was measured as described by Schofield et al. (20) .
Results
Imidazole antimycotics inhibit Ca2--activated 86Rb influx in SS erythrocytes. The inhibitory effect of CLT on the Ca2+-activated 86Rb influx of SS cells from three patients was assessed in low ionic strength media (18 mM NaCl, 2 mM KCI, 230 mM sucrose) and in normal saline (140 mM NaCl, 2 mM KCl) in the presence of 50 ,uM CaCl2 and 60 ,umol A23 187/liter cell. As shown in Fig. 1 A, CLT markedly inhibited Ca2+-activated 86Rb influx. For red cells from each patient, the inhibition was greater when measured at low ionic strength. Mean values of IC50±SD were 29±15 nM (n = 3) at low ionic strength and 51±15 nM (n = 3) for normal saline.
Other antimycotic drugs were tested for their ability to inhibit Ca2+-activated 86Rb influx in sickle erythrocytes. As shown in Table I , the rank order of inhibitory potency determined in normal saline was clotrimazole (IC,0 = 51 ± 15 nM) = miconazole (ICm = 110 nM) > econazole (ICm = 270 nM), with no inhibition by fluconazole. The degree oftransport inhibition produced by 10 ,uM clotrimazole (87%) was significantly greater than with 10 ,M miconazole (63%). 86Rb influx was partially inhibited by metronidazole (IC50 = 440 nM), a member ofthe nitroimidazole class, but only marginally by 10 ,uM ornidazole and tinidazole, two other members ofthis class.
To address the specificity ofaction ofthe imidazole antimycotics, we assessed the effect of these drugs on "S-sulfate influx into normal human red cells (sulfate/chloride exchange, reference 20). This assay is an index of function of the major anion transport system of red cells, the AEl (band 3) chloride/bicarbonate exchanger (21) . We found no inhibition of AEl function by any ofthe above-mentioned compounds at 10 gM concentrations (not shown). Gardos channel-mediated cell shrinkage requires net movement of Cl-or another anion to accompany K loss from the cell. AE1 is thought to mediate the dominant Cl-conductance ofthe red cell membrane, as well as the much greater, electrically silent membrane permeability to Cl-. Thus, the lack of inhibition of sulfate uptake by CLT makes primary inhibition of electrogenic anion permeability an unlikely explanation for the inhibitory effect of CLT on Ca2+-activated 86Rb influx. Furthermore, there was no effect of 10 ,uM or of 1 ,sM CLT on the activities in normal human red cells ofthe Na-K pump, Na-K-Cl cotransport, or K-Cl cotransport (not shown).
When the Gardos channel is activated, the increased membrane permeability for K+ shifts the membrane potential away from the equilibrium potential for Cl-(EC,) toward the equilibrium potential for K+ (EK). This effect is magnified when the membrane Cl-permeability is inhibited by DIDS (18) . The effect of CLT on the membrane potential of SS cells in which the Gardos channel is activated is shown in Fig. 1 B. CLT markedly reduced K+ permeability and shifted Em from EK toward Ea. The inhibitory potency of CLT in this assay was higher in low ionic strength conditions than in normal saline ( Fig. 1 B, IC50 values of 33±6 nM and 208±13 nM, respectively).
Imidazole antimycotics displace bound '25I-ChTXfrom SS erythrocytes. '25I-ChTX is a specific ligand of the Ca2+-activated K+ channel of human red cells. In normal red cells, 60-70% of the total binding can be displaced by an excess (50 nM) of cold ChTX (16) . Levels of specific binding of '25I-ChTX are more heterogeneous in SS patients, with markedly increased specific binding in the least dense cells (14) . To examine the interaction between CLT and the Ca2+-activated K+ channel of SS cells, we measured displacement of '25I-ChTX (50 pM) bound to SS cells by increasing concentrations of CLT. As shown in Fig. 1 C, in the same range as the IC50 for inhibition of Ca2"-activated 86Rb influx (29±15 nM). Other imidazole antimycotics that inhibited Ca2+-activated 86Rb influx also displaced specifically bound 1251-ChTX from sickle erythrocytes ( Table I ). The IC50 values for flux inhibition and for '25I-ChTX displacement by the active inhibitors tested showed reasonably good agreement. Imidazole antimycotics block Ca2+-dependent dehydration of SS erythrocytes. Several protocols of deoxygenation have been used to demonstrate the role of the Ca2+-activated K channel in promoting sickle cell dehydration (7, 8, 13, 22) . We first assessed the inhibitory effect of CLT and other antimycotics on the dehydration mediated by the Ca2+-activated K+ channel under conditions of maximal activation of this pathway by exposure to A23187 for 15 min in the presence of 100 ,uM CaC12. After rapid removal of ionophore and chelation of Ca2 , single cell volume and hemoglobin concentration were measured with the (Technicon H*2; Miles Diagnostics Inc.) blood analyzer. (Fig. 2 A, left column) . The presence of 10 ,qM CLT substantially prevented this dehydration such that the HC and volume distributions of SS cells reverted nearly to those of control conditions (Fig. 2 A, right column) . Measurements of cell cation content at the end of the incubation supported the hypothesis that the effects of CLT on volume and HC were caused by inhibition of K loss. Mean values from experiments with SS cells from three individuals indicated that cell K was decreased in the presence of Ca2", and this change was markedly inhibited by 10 AM CLT (Table II) . Similar experiments were carried out with miconazole and econazole at 10 gM concentrations, but the inhibitory effects on dehydration were substantially smaller than those observed for CLT (not shown).
To evaluate the effect of CLT on the changes in cation content induced by deoxygenation, SS cells were exposed for periods of 1-3 h to repeated cycles of4 min deoxygenation and 1 min oxygenation. As shown in Fig. 2 B, this deoxygenation protocol produced a Ca2+-dependent cell dehydration of lesser degree than did A23187. This dehydration was inhibited to equal extent by Ca2+ chelation with EGTA or by 10 ,uM CLT.
Similar experiments for SS cells from three individuals are summarized in part B of Table II. Table II also documents the ability of CLT to prevent completely the deoxygenation-induced, Ca2+-dependent loss of cellular K+.
Discussion
We have demonstrated in this report that imidazole derivatives are potent and specific inhibitors of the Ca2+-activated K+ channel (Gardos channel) of sickle erythrocytes. CLT appears to be the most potent inhibitor of the Gardos channel of sickle cells among the tested members of this class of compounds. CLT displayed IC50 values for inhibition of Ca2+-activated K+ transport of 29±15 nM in low ionic strength medium and 51 ± 15 nM at physiologic ionic strength (Fig. 1 A) . Similar values were obtained for the inhibition by CLT of the membrane potential changes induced by activation ofthe Gardos channel in sickle erythrocytes (Fig. 1 B) . CLT also displaced bound '25I-ChTX, a specific ligand for the Ca2+-activated K channel of human red cells (16) with an IC50 (12±4 nM) similar to that for its inhibition of 86Rb transport (Fig. 1 C) . In addition, CLT markedly inhibited the dehydration of sickle cells induced by activation of the Gardos channel, whether by A23 187 or by cycles of oxygenation-deoxygenation ( Fig. 2 and Table II) .
Based on the similarities in the IC50 values ofCLT for inhibition of 86Rb influx influx and for displacement of '25I-ChTX, we propose that CLT inhibits the Gardos channel by direct binding to an inhibitory site on the external surface ofthe channel which partially overlaps with the ChTX binding site or otherwise promotes ChTX dissociation. The inhibition by CLT of net K+ efflux was probably not secondary to blockage of the anion permeability, since the AE-1-mediated influx of sulfate was not decreased by CLT. This lack ofeffect ofCLT on anion permeability was also observed in normal red cells by Alvarez et al. (15) .
Other imidazole antimycotics, as well as nitroimidazole derivatives, were tested for their inhibitory potencies on the Gardos pathway. Important differences were found among the drugs in IC50 for 86Rb influx inhibition and in the maximal inhibition achieved by lo0 M concentrations. The Though CLT has been shown also to inhibit cytochrome P450 activity and plasmalemmal calcium influx (15) , the data pre- (30) .
sented in this paper suggest that these lower affinity actions of CLT probably play little or no role in the ability of CLT to inhibit the Gardos pathway. Generation of irreversibly sickled cells under conditions of ATP depletion has been shown to depend on the presence of external Ca2". The possible involvement ofthe Gardos effect in this phenomenon was first advocated by Glader and Nathan in 1978 (7). However, they also found that deoxygenation in the absence of ATP depletion did not change the total cation content of red cells. Experiments performed in thiocyanate (SCN-) media have indicated that Ca2+-dependent K+ loss does take place during deoxygenation and is associated with formation of dense cells (8) . The integrated red cell model developed by Lew and Bookchin suggests a major role for the Gardos pathway in cell dehydration (23) . Experiments in SS reticulocytes have shown that 30 min deoxygenation in the presence of Ca-2 induces significant dehydration that can be blocked by quinine, a low affinity inhibitor of the Gardos pathway (24) .
Antimycotics of the imidazole class include clotrimazole, miconazole, ketoconazole, and econazole, whereas terconazole, itraconazole, and fluconazole are members ofthe triazole class (25) . Their antimycotic effects have been attributed to their inhibition of fungal sterol-14-demethylase, a cytochrome P-450 dependent system (25) . All these drugs are available as topical preparations, and a number are available for intravenous administration. CLT, ketoconazole and itraconazole, can also be administered orally. Side effects of oral CLT include infrequent nausea, vomiting, diarrhea, and very infrequent neurologic effects. The latter, however, have been attributed to release ofendotoxins from lysed fungi (26) . Plasma levels ofthe drug in patients receiving two oral doses of I g spaced 4 h apart varied between 1.2 and 4 ,g/ml at 9-12 h after the second dose (27) . These levels correspond to plasma concentrations of 3.5-11.6 ueM. Another study that administered CLT in three daily oral doses of 20 mg/kg body wt reported serum levels between 0.3 and 1 gg/ml, corresponding to 0.9-2.9 MiM (28) Oral doses of 522 and 1,000 mg of miconazole in normal subjects yielded peak plasma concentrations of 0.37-1. 16 ,g/ ml (0.77-2.42 ,M; reference 29). However, use of intravenous miconazole is associated with phlebitis, pruritus, nausea, fever, and chills in 11-28% of patients and, more importantly, with anemia secondary to marrow hypoplasia in 40-50% ofpatients (29) . This hematologic side effect probably will prohibit trials of miconazole in SS disease. Fluconazole, the only triazole antimycotic that has been extensively studied with systemic administration, does not inhibit the Ca2+-activated K+ channel of SS cells.
Among the compounds tested here, CLT displayed the most potent and the most complete inhibition ofthe Ca2+-activated K+ channel of sickle cells. Most importantly, the measured IC50 for inhibition of 86Rb influx by CLT is lower than the levels achievable in plasma after oral administration. CLT plasma and serum levels reported in the literature after high but nontoxic doses are 10-50-fold higher than the IC50 for inhibition of 86Rb influx, suggesting that nearly complete inhibition of the Gardos pathway might be therapeutically achievable. High dose oral CLT administration also has been associated with relatively mild side effects.
In conclusion, the widely used, inexpensive drug clotrimazole is a potent and specific inhibitor of the Ca2+-activated K+ channel of sickle erythrocytes. The ratio between clinically achievable plasma concentrations and in vitro inhibitory potency, together with the relatively mild side effects, suggest that it could be used to prevent dehydration of SS cells in vivo. Clotrimazole may also lend itself to combination therapy with other promising therapeutic agents such as hydroxyurea and sodium phenylbutyrate.
